CHA Vaccine Amends Paid-in Capital Increase
아리바이오LAB
261780
Signal Score
Historical Avg Return (5d)
+0.33%
Data Coverage
100%n=2377
Risk-adjusted indicator based on 2377 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Shares Issued: 1,100,917 Shares (down from 1,834,862 Shares)
- • Funding Size: 2,999,998,825 KRW (down from 4,999,998,950 KRW)
- • New Allottee: ARI BIO Co., Ltd. (previously Dream High Holdings Co., Ltd.)
- • Payment Date: June 30, 2026 (previously June 25, 2026)
- • Listing Date: July 15, 2026 (previously July 10, 2026)
AI Analysis Summary
CHA Vaccine Research Institute announced an amendment to its paid-in capital increase. The number of new shares to be issued has been reduced from 1,834,862 to 1,100,917, decreasing the total funding from 4,999,998,950 KRW to 2,999,998,825 KRW. The allottee for this third-party allocation has changed from Dream High Holdings Co., Ltd. to ARI BIO Co., Ltd., a related company. The payment date is now June 30, 2026, with a listing date of July 15, 2026. The purpose remains financial structure improvement and strategic business cooperation. While the dilution is reduced, the change in allottee to a related company might be viewed neutrally.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.